(Press-News.org) An analysis of a cardiovascular registry finds that of clinical trials that included heart attack patients, participation among eligible patients was infrequent and has been declining, and trial participants had a lower risk profile and a more favorable prognosis compared with the broader population of patients who have had a heart attack, according to a study in the August 27 issue of JAMA.
Jacob A. Udell, M.D., M.P.H., of the University of Toronto, and colleagues evaluated whether participants in cardiovascular trials are representative of contemporary patients with myocardial infarction (MI; heart attack). The researchers used data from the National Cardiovascular Data Registry Acute Coronary Treatment and Intervention Outcomes Network Registry-Get With The Guidelines, an ongoing, voluntary, quality improvement registry of patients with MI treated at participating centers across the United States.
Among 141,135 registry participants at 466 centers, 4,008 (2.8 percent) were trial participants; among the 137,127 nonparticipants, 93,274 were eligible (68.0 percent) and 43,853 were ineligible (32.0 percent). Overall, 255 sites (54.7 percent) enrolled at least 1 patient; and trial participation (as a proportion of eligible patients) declined each year during the study period (2008: 5.2 percent; 2009: 4.4 percent; 2010: 3.8 percent; and 2011: 3.4 percent). Trial participants were younger, with less previous cardiovascular disease, lower predicted risk of mortality, shorter hospital stays, and more frequent treatment with evidencebased therapy than nonparticipants.
Common reasons for trial ineligibility included uncontrolled hypertension, elevated INR (abnormal clotting), severe anemia, and cardiogenic shock. In-hospital mortality was lowest for trial participants, intermediate among eligible nonparticipants, and highest among ineligible patients.
"Efforts to improve trial participation are needed to enhance generalizability of results," the authors write.
INFORMATION:
doi:10.1001/jama.2014.6217
Available pre-embargo to the media at http://media.jamanetwork.com
Editor's Note: Please see the article for additional information, including other authors, author contributions and affiliations, financial disclosures, funding and support, etc.
Study questions generalizability of findings of CV trials for heart attack patients
2014-08-26
ELSE PRESS RELEASES FROM THIS DATE:
EPO: Protecting the brains of very preterm infants
2014-08-26
Premature babies are far more at risk than infants born at term of developing brain damage resulting in neurodevelopmental delay that may persist throughout their lives. A team of specialists in infant brain imaging from the Faculty of Medicine at the University of Geneva (UNIGE) and the University Hospital of Geneva (HUG) has demonstrated the following: administering three doses of erythropoietin – a hormone that stimulates the formation of red blood cells – immediately after birth significantly reduces brain damage in babies. The results are available in more detail in ...
Collaborative care improves depression in teens
2014-08-26
SEATTLE—How best to care for the many adolescents who have depression? In a collaborative care intervention, a care manager continually reached out to teens—delivering and following up on treatment in a primary-care setting (the office of a pediatrician or family doctor, not a psychiatrist or psychologist) at Group Health Cooperative. Depression outcomes after a year were significantly better with this approach than with usual care, according to a randomized controlled trial published in JAMA.
Depression is common in adolescents: Up to one in five have major depression ...
Attacking a rare disease at its source with gene therapy
2014-08-26
PHILADELPHIA — Treating the rare disease MPS I is a challenge. MPS I, caused by the deficiency of a key enzyme called IDUA, eventually leads to the abnormal accumulation of certain molecules and cell death.
The two main treatments for MPS I are bone marrow transplantation and intravenous enzyme replacement therapy, but these are only marginally effective or clinically impractical, especially when the disease strikes the central nervous system (CNS). Using an animal model, a team from the Perelman School of Medicine at the University of Pennsylvania has proven the efficacy ...
Unprecedented detail of intact neuronal receptor offers blueprint for drug developers
2014-08-26
Argonne, Ill.– Scientists succeeded in obtaining an unprecedented view of a type of brain-cell receptor that is implicated in a range of neurological illnesses, including Alzheimer's disease, Parkinson's disease, depression, schizophrenia, autism, and ischemic injuries associated with stroke.
The team of biologists at Cold Spring Harbor Laboratory used the U.S. Department of Energy's Advanced Photon Source at Argonne National Laboratory to get an atomic-level picture of the intact NMDA (N-methyl, D-aspartate) receptor should serve as template and guide for the design ...
Yale journal explores advances in sustainable manufacturing
2014-08-26
In recent years, increasing pressure from policymakers, consumers, and suppliers has prompted manufacturers to set environmental targets that go beyond reducing the pollutants they emit from their smokestacks or discharge into rivers and lakes. Today companies must also assess environmental performance at every step in their process, from the mining of primary materials to the use and recycling of their products.
This perspective has given rise to the discipline known as life cycle engineering, which connects the engineers who grapple with the efficiencies of production ...
Composition of Earth's mantle revisited
2014-08-26
Research published recently in Science suggested that the makeup of the Earth's lower mantle, which makes up the largest part of the Earth by volume, is significantly different than previously thought.
Understanding the composition of the mantle is essential to seismology, the study of earthquakes and movement below the Earth's surface, and should shed light on unexplained seismic phenomena observed there.
Though humans haven't yet managed to drill further than seven and a half miles into the Earth, we've built a comprehensive picture of what's beneath our feet through ...
What can 14th century Venice teach us about Ebola and other emerging threats?
2014-08-26
The way in which the Italian city of Venice dealt with the outbreak of the plague in the fourteenth century holds lessons on how to even mitigate the consequences of today's emerging threats, like climate change, terrorism, and highly infectious or drug-resistant diseases. So says Dr. Igor Linkov of the US Army Engineer Research and Development Center, and a visiting professor of the Ca Foscari University in Italy. Linkov led an article on resilience management appearing in Springer's journal Environment Systems and Decisions.
Venice was the hub of many trade routes into ...
Sorting cells with sound waves
2014-08-26
CAMBRIDGE, MA -- Researchers from MIT, Pennsylvania State University, and Carnegie Mellon University have devised a new way to separate cells by exposing them to sound waves as they flow through a tiny channel. Their device, about the size of a dime, could be used to detect the extremely rare tumor cells that circulate in cancer patients' blood, helping doctors predict whether a tumor is going to spread.
Separating cells with sound offers a gentler alternative to existing cell-sorting technologies, which require tagging the cells with chemicals or exposing them to stronger ...
Introducing the multi-tasking nanoparticle
2014-08-26
(SACRAMENTO, Calif.) — Kit Lam and colleagues from UC Davis and other institutions have created dynamic nanoparticles (NPs) that could provide an arsenal of applications to diagnose and treat cancer. Built on an easy-to-make polymer, these particles can be used as contrast agents to light up tumors for MRI and PET scans or deliver chemo and other therapies to destroy tumors. In addition, the particles are biocompatible and have shown no toxicity. The study was published online today in Nature Communications.
"These are amazingly useful particles," noted co-first author ...
HIV antibodies block infection by reservoir-derived virus in laboratory study
2014-08-26
WHAT:
A laboratory study led by scientists from the National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health (NIH), lends further weight to the potential effectiveness of passive immunotherapy to suppress HIV in the absence of drug treatment. Passive immunotherapy for HIV is an experimental strategy that involves periodically administering broadly neutralizing HIV-specific antibodies (bNAbs) to control the virus. It would be advantageous to control HIV without antiretroviral drugs because of their cost, the potential for cumulative ...